Sumitomo Mitsui Asset Management Company LTD Takes Position in Neurocrine Biosciences, Inc. (NBIX)

Share on StockTwits

Sumitomo Mitsui Asset Management Company LTD bought a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 4,725 shares of the company’s stock, valued at approximately $416,000.

Other institutional investors also recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth $32,000. Exane Derivatives raised its position in Neurocrine Biosciences by 48,400.0% during the fourth quarter. Exane Derivatives now owns 485 shares of the company’s stock valued at $35,000 after buying an additional 484 shares during the period. Quadrant Capital Group LLC raised its position in Neurocrine Biosciences by 9,242.9% during the first quarter. Quadrant Capital Group LLC now owns 654 shares of the company’s stock valued at $56,000 after buying an additional 647 shares during the period. Penserra Capital Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $86,000. Finally, Arbor Wealth Management LLC acquired a new position in Neurocrine Biosciences during the fourth quarter valued at $92,000.

NBIX has been the topic of several recent analyst reports. Needham & Company LLC lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, January 24th. Oppenheimer set a $105.00 price target on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, January 29th. Cantor Fitzgerald reissued a “buy” rating and set a $121.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, January 29th. HC Wainwright reissued a “buy” rating on shares of Neurocrine Biosciences in a research report on Wednesday, January 30th. Finally, Bank of America dropped their price target on Neurocrine Biosciences from $124.00 to $117.00 and set a “buy” rating on the stock in a research report on Wednesday, February 6th. Five research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Neurocrine Biosciences currently has an average rating of “Buy” and an average price target of $102.95.

In other Neurocrine Biosciences news, insider Haig P. Bozigian sold 34,547 shares of the company’s stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $75.51, for a total value of $2,608,643.97. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Haig P. Bozigian sold 1,300 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $80.03, for a total value of $104,039.00. Following the sale, the insider now owns 143,276 shares of the company’s stock, valued at approximately $11,466,378.28. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,514 shares of company stock worth $8,054,710. Insiders own 4.30% of the company’s stock.

NBIX stock traded up $0.49 during mid-day trading on Friday, hitting $79.24. The stock had a trading volume of 8,239 shares, compared to its average volume of 947,659. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.79 and a quick ratio of 8.61. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $126.98. The firm has a market cap of $7.27 billion, a P/E ratio of 362.55 and a beta of 1.73.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Monday, April 29th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.07). Neurocrine Biosciences had a negative return on equity of 9.14% and a negative net margin of 7.56%. The firm had revenue of $138.40 million during the quarter, compared to analyst estimates of $136.77 million. During the same period in the previous year, the company earned ($0.47) earnings per share. The business’s revenue for the quarter was up 94.7% on a year-over-year basis. As a group, research analysts expect that Neurocrine Biosciences, Inc. will post -0.24 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/4351517/sumitomo-mitsui-asset-management-company-ltd-takes-position-in-neurocrine-biosciences-inc-nbix.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

Further Reading: How to invest in blue-chip stocks

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

GeneNews   Shares Down 7.7%
GeneNews Shares Down 7.7%
Analyzing Barings BDC  and Great Elm Capital
Analyzing Barings BDC and Great Elm Capital
Caterpillar  Given a $115.00 Price Target at Macquarie
Caterpillar Given a $115.00 Price Target at Macquarie
Avantor  Research Coverage Started at Citigroup
Avantor Research Coverage Started at Citigroup
Insider Buying: TransAtlantic Petroleum Ltd  CEO Buys 6,772,612 Shares of Stock
Insider Buying: TransAtlantic Petroleum Ltd CEO Buys 6,772,612 Shares of Stock
POSCO  Holdings Raised by Alera Investment Advisors LLC
POSCO Holdings Raised by Alera Investment Advisors LLC


© 2006-2019 Ticker Report